Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey
Continuous improvements in the tisagenlecleucel manufacturing process over the years resulted in higher manufacturing success and increased product availability for Japanese patients.
Authors
- David Fong
- Margarida Rodrigues (ORCID: https://orcid.org/0000-0003-4658-6281)
- Yoshie Tsurumaki
- Fumiko Iwamoto
Institutions
- Novartis (Japan) (JP)
- Laboratório Edol (Portugal) (PT)
- Novartis (Canada) (CA)
Publication Details
- Journal
- Regenerative Therapy
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.reth.2025.02.001
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Novartis Pharmaceuticals Corporation